Calando Pharmaceuticals, Inc. is a privately held, focused on developing targeted therapeutics that take advantage of the potential of its patented and proprietary cyclodextrin-based polymer technologies for the development of nanoparticle therapeutics. Calando is a subsidiary of Arrowhead Research Corporation.

Acquired Companies: Insert Therapeutics, Inc.